153 related articles for article (PubMed ID: 21317816)
1. Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment.
Hariharan V; Toole T; Klarquist J; Mosenson J; Longley BJ; Le Poole IC
Melanoma Res; 2011 Apr; 21(2):115-26. PubMed ID: 21317816
[TBL] [Abstract][Full Text] [Related]
2. Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin.
Bonchak JG; Eby JM; Willenborg KA; Chrobak D; Henning SW; Krzywiec A; Johnson SL; Le Poole IC
Arch Biochem Biophys; 2014 Dec; 563():71-8. PubMed ID: 25132642
[TBL] [Abstract][Full Text] [Related]
3. Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation.
Hariharan V; Klarquist J; Reust MJ; Koshoffer A; McKee MD; Boissy RE; Le Poole IC
J Invest Dermatol; 2010 Jan; 130(1):211-20. PubMed ID: 19657355
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid synergistically enhances the melanocytotoxic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin.
Kasraee B; Fallahi MR; Ardekani GS; Ebrahimi S; Doroudchi G; Omrani GR; Handjani F; Amini M; Tanideh N; Haddadi M; Nikbakhsh M; Jahanbani S; Tran C; Sorg O; Saurat JH
Exp Dermatol; 2006 Jul; 15(7):509-14. PubMed ID: 16761959
[TBL] [Abstract][Full Text] [Related]
5. Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.
Webb KC; Eby JM; Hariharan V; Hernandez C; Luiten RM; Le Poole IC
Exp Dermatol; 2014 Aug; 23(8):529-33. PubMed ID: 24840876
[TBL] [Abstract][Full Text] [Related]
6. Effects of Monobenzyl ether of hydroquinone on 3T3 mouse fibroblast viability and ultrastructure.
Erdoğan A; Mutlu HS; Doğan S; Kotil T
Ultrastruct Pathol; 2021 Nov; 45(6):384-390. PubMed ID: 34875974
[TBL] [Abstract][Full Text] [Related]
7. Influence of depigmenting chemical agents on hair and skin color in yellow (pheomelanic) and black (eumelanic) mice.
Quevedo WC; Holstein TJ; Dyckman J; Nordlund JJ
Pigment Cell Res; 1990; 3(2):71-9. PubMed ID: 2385568
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the population density of identifiable epidermal Langerhans cells associated with enhancement or suppression of cutaneous immune reactivity.
Rheins LA; Nordlund JJ
J Immunol; 1986 Feb; 136(3):867-76. PubMed ID: 3079801
[TBL] [Abstract][Full Text] [Related]
9. Chemical induced pathognomonic features observed in human vitiligo are mediated through miR-2909 RNomics pathway.
Kaushik H; Kaul D; Kumaran MS; Parsad D
J Dermatol Sci; 2020 Nov; 100(2):92-98. PubMed ID: 33039241
[TBL] [Abstract][Full Text] [Related]
10. Rapid induction of Thy-1 antigenic markers on keratinocytes and epidermal immune cells in the skin of mice following topical treatment with common preservatives used in topical medications and in foods.
Rheins LA; Young EM; Nordlund ML; Berning RB; Nordlund JJ
J Invest Dermatol; 1987 Nov; 89(5):489-94. PubMed ID: 2889782
[TBL] [Abstract][Full Text] [Related]
11. Depigmentation therapies for normal skin in vitiligo universalis.
AlGhamdi KM; Kumar A
J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):749-57. PubMed ID: 21054565
[TBL] [Abstract][Full Text] [Related]
12. [Acquired leukomelanoderma caused by topical depigmenting agents].
Grojean MF; Thivolet J; Perrot H
Ann Dermatol Venereol; 1982; 109(8):641-7. PubMed ID: 7187189
[TBL] [Abstract][Full Text] [Related]
13. Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.
van den Boorn JG; Konijnenberg D; Tjin EP; Picavet DI; Meeuwenoord NJ; Filippov DV; van der Veen JP; Bos JD; Melief CJ; Luiten RM
PLoS One; 2010 May; 5(5):e10626. PubMed ID: 20498710
[TBL] [Abstract][Full Text] [Related]
14. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Najar HM; Dutz JP
J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
[TBL] [Abstract][Full Text] [Related]
15. Depigmentation therapies in vitiligo.
Gupta D; Kumari R; Thappa DM
Indian J Dermatol Venereol Leprol; 2012; 78(1):49-58. PubMed ID: 22199060
[TBL] [Abstract][Full Text] [Related]
16. Langerhans' cells in hair follicles of the depigmenting C57Bl/Ler-vit.vit mouse. A model for human vitiligo.
Palkowski MR; Nordlund ML; Rheins LA; Nordlund JJ
Arch Dermatol; 1987 Aug; 123(8):1022-8. PubMed ID: 2443080
[TBL] [Abstract][Full Text] [Related]
17. Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature.
Mosher DB; Parrish JA; Fitzpatrick TB
Br J Dermatol; 1977 Dec; 97(6):669-79. PubMed ID: 603749
[TBL] [Abstract][Full Text] [Related]
18. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration.
Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
J Invest Dermatol; 2000 Dec; 115(6):1059-64. PubMed ID: 11121142
[TBL] [Abstract][Full Text] [Related]
19. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
Garbelli S; Mantovani S; Palermo B; Giachino C
Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
[TBL] [Abstract][Full Text] [Related]
20. [Leukoderma caused by chemicals: mechanisms underlying 4-alkyl/aryl-substituted phenols- and rhododendrol-induced melanocyte loss].
Nishimaki-Mogami T
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2015; (133):13-20. PubMed ID: 26821466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
